Immatics (IMTX) Net Income towards Common Stockholders (2019 - 2025)
Immatics (IMTX) posted Net Income towards Common Stockholders of -$41.2 million for Q4 2025, up 30.55% sequentially from -$59.4 million in Q3 2025, and down 186.03% YoY from $47.9 million in Q4 2024.
Immatics (IMTX) Net Income towards Common Stockholders (2019 - 2025) Analysis & Trends
Immatics has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$41.2 million in Q4 2025.
- Quarterly Net Income towards Common Stockholders fell 186.03% year-over-year to -$41.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$224.3 million (down 1600.78% YoY) and the FY2025 annual result came in at -$221.9 million, down 1447.51% from the prior year.
- Net Income towards Common Stockholders improved to -$41.2 million in Q4 2025 per IMTX's latest filing, from -$59.4 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $96.1 million in Q1 2022 and troughed at -$79.6 million in Q2 2025.
- A 5-year average of -$16.9 million and a median of -$23.4 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders soared 449.38% in 2022, then tumbled 135050064.49% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$19.2 million in 2021, then surged by 111.78% to $2.3 million in 2022, then tumbled by 1343.81% to -$28.1 million in 2023, then soared by 270.4% to $47.9 million in 2024, then sank by 186.03% to -$41.2 million in 2025.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$41.2 million, -$59.4 million, and -$79.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Immatics | 1.27 Bn | 719.31 Mn | - | -1.53 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -41.24 Mn |
| Sep 30, 2025 | -59.39 Mn |
| Jun 30, 2025 | -79.63 Mn |
| Mar 31, 2025 | -44.01 Mn |
| Dec 31, 2024 | 47.94 Mn |
| Sep 30, 2024 | -13.62 Mn |
| Jun 30, 2024 | -19.38 Mn |
| Mar 31, 2024 | -32.59 |
| Dec 31, 2023 | -28.13 Mn |
| Sep 30, 2023 | -28.84 Mn |
| Jun 30, 2023 | -26.80 Mn |
| Mar 31, 2023 | -279.07 |
| Dec 31, 2022 | 2.26 Mn |
| Sep 30, 2022 | -19.98 Mn |
| Jun 30, 2022 | -12.47 Mn |
| Mar 31, 2022 | 96.14 Mn |
| Dec 31, 2021 | -19.20 Mn |
| Sep 30, 2021 | -32.08 Mn |
| Jun 30, 2021 | -31.95 Mn |
| Mar 31, 2021 | -27.52 Mn |